triple antagonist glp-1 Agonism Based Therapies for Obesity Science's 2023 Breakthrough: GLP-1R Agonists
Description
Recovery Centers of Americas Chief Medical Officer Jason Kirby, DO, MBA, DFASAM, recently authored an article featured in Drug Discovery Online.
What to expect first day of GLP-1 medication
Discover the research linking semaglutide to LDL reduction and HDL improvement
But for some, the drugs come with side effects they say aren't worth it.
Pendulum Akkermansia 500 Pro is a targeted next-generation probiotic formulated to support gut barrier integrity, microbial diversity, and metabolic wellness
As of early 2026, several potent single, dual, and triple incretin receptor agonists are in Phase 2/3 trials for MASH including : Survodutide : A dual glucagon (GCGR)/GLP-1 receptor agonist that has shown significant MASH resolution in Phase 2 trials
